Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IEAC conditioning followed by autologous stem cell transplantation for malignant lymphoma
ChiCTR1800016944Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Sep 2018
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of idarubicin, etoposide, cytarabine and cyclophosphamide in lymphosarcoma, sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoint: overall survival. Started Sep 2018; status: recruiting.
02
Drugs
idarubicinetoposidecytarabinecyclophosphamide
03
Conditions
lymphosarcoma
Beyond the preview
Go deeper on ChiCTR1800016944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016944.